Company: HCTI
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026218
Chunk: 698

Company: Healthcare Triangle, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 698
---

Net cash used in investing activities was $0 million
for the twelve months ended December 31, 2024, and $0.013	 million for the twelve months ended December 31, 2023.

Financing Activities

Cash flows from financing activities was $0.135
million for the twelve months ended December 31, 2024, and $2 million for the twelve months ended December 31, 2023.

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated
organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the
purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes as defined by Item 303(a)(4)
of SEC Regulation S-K, as of December 31, 2024.

46

Item 8. Financial Statements and Supplementary Data

HEALTHCARE TRIANGLE, INC.

Consolidated Financial Statements

December 31, 2024 and 2023

  Report of Independent Registered Public Accounting Firm PCAOB ID 2738 F-2  Financial Statements    Consolidated Balance Sheets as of December 31, 2024 and 2023 F-3  Consolidated Statements of Operations For The Years Ended December 31, 2024 and 2023 F-4  Consolidated Statements of Changes in Stockholders’ Equity (Deficit) For The Years Ended December 31, 2024 and 2023 F-5  Consolidated Statements of Cash Flows For The Years Ended December 31, 2024 and 2023 F-6  Notes to Consolidated Financial Statements F-7 

F-1

Report of Independent Registered Public Accounting
Firm

To the Board of Directors and

Stockholders of Healthcare
Triangle, Inc.

Opinion on the Financial Statements

We have audited the accompanying
consolidated balance sheets of Healthcare Triangle, Inc. (the Company) as of December 31, 2024 and 2023, and the related consolidated
statements of operations, stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December
31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023,